Related Experiment Video
Updated: Jun 6, 2026

Generation of Lymphocytic Microparticles and Detection of their Proapoptotic Effect on Airway Epithelial Cells
Published on: February 20, 2015
Microparticles: key protagonists in cardiovascular disorders
Nicolas Amabile1, Pierre-Emmanuel Rautou, Alain Tedgui
1INSERM, U970, Paris Cardiovascular Research Center - PARCC, Paris, France.
Abstract:
Microparticles (MP) are shed membrane vesicles released by various cell types following apoptosis or activation. MP circulate in human plasma and also accumulate in atherosclerotic lesions. A growing body of evidence has highlighted their involvement in inflammation, angiogenesis, coagulation, and the regulation of vascular tone. MP may therefore contribute to the initiation and development of atherosclerosis and its complications. Plasma MP originate from platelets, leukocytes, erythrocytes, and endothelial cells, and their levels increase in patients with cardiovascular diseases; specific cardiovascular medications also affect plasma MP levels. Most recent data suggest a potential prognostic role of circulating MP for identification of subjects prone to develop cardiovascular complications.
Insights
Circulating microparticles (MPs), which are cell-derived vesicles, are linked to inflammation and blood vessel health. Elevated MP levels in cardiovascular disease patients may predict future complications.
Area of Science:
- Cardiovascular Biology
- Cellular Biology
- Biochemistry
Background:
- Microparticles (MPs) are membrane vesicles released from cells during apoptosis or activation.
- These circulating MPs are found in human plasma and atherosclerotic lesions.
- MPs play roles in inflammation, angiogenesis, coagulation, and vascular tone regulation.
Purpose of the Study:
- To investigate the role of microparticles in atherosclerosis.
- To examine the origin and clinical significance of plasma MPs.
Main Methods:
- Analysis of plasma microparticle levels.
- Correlation of microparticle levels with cardiovascular disease status and medications.
Main Results:
- Plasma microparticle levels are elevated in patients with cardiovascular diseases.
- Specific cardiovascular medications influence plasma microparticle levels.
- Circulating MPs show potential as prognostic markers for cardiovascular complications.
Conclusions:
- Microparticles contribute to the development of atherosclerosis and its complications.
- Plasma microparticle levels can serve as a prognostic indicator for cardiovascular disease risk.
Related Concept Videos
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease I: Introduction
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Lipid-derived Compounds in the Human Body
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin, delayed...
Cardiovascular Drugs: Classification based on Therapeutic Indications